<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2025.1638611</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Correction: Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibiting <italic>Porphyromonas gingivalis</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Production Office</collab>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/20170/overview"/>
</contrib>
</contrib-group>
<aff><institution>Frontiers Media SA</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Frontiers Production Office <email>production.office&#x00040;frontiersin.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>07</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1638611</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2025 Frontiers Production Office.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Frontiers Production Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front. Microbiol." journal-id-type="nlm-ta" vol="16" page="1531258" xlink:href="10.3389/fmicb.2025.1531258" ext-link-type="doi">A Correction on <article-title>Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibiting <italic>Porphyromonas gingivalis</italic></article-title> by Wang, Y., Ma, J., Wang, H., Yi, J., Bai, Y., Hu, M., and Yan, J. (2025). <italic>Front. Microbiol</italic>. 16:1531258. doi: <object-id>10.3389/fmicb.2025.1531258</object-id></related-article>
<kwd-group>
<kwd>periodontitis</kwd>
<kwd>mesalazine</kwd>
<kwd><italic>Porphyromonas gingivalis</italic></kwd>
<kwd>plaque biofilm</kwd>
<kwd>inflammatory bowel disease</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="3"/>
<word-count count="554"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Antimicrobials, Resistance and Chemotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In the published article, there was an error in <xref ref-type="fig" rid="F1">Figures 2E</xref>, <xref ref-type="fig" rid="F1">2H</xref>, <xref ref-type="fig" rid="F2">4E</xref> as published. The micrometers on the scale were erroneously written as nanometers. The corrected <xref ref-type="fig" rid="F1">Figures 2E</xref>, <xref ref-type="fig" rid="F1">2H</xref>, <xref ref-type="fig" rid="F2">4E</xref>, and their respective captions, appear below.</p>
<fig id="F1" position="float">
<label>Figure 2</label>
<caption><p>Preventive anti-biofilm potential of MSZ. <bold>(A)</bold> Effect of 0.5 mg/mL and 1 mg/mL MSZ on the overall biomass of <italic>P. gingivalis</italic> plaque biofilm formation and established plaque biofilms. <bold>(B)</bold> Histograms of the overall biomass of <italic>P. gingivalis</italic> plaque biofilm formation. <bold>(C)</bold> Histograms depicting total biomass distribution of pre-formed plaque biofilm spread. <bold>(D)</bold> Metabolic activity during plaque biofilm formation and <bold>(E)</bold> CLSM images of <italic>P. gingivalis</italic> plaque biofilm formation, including pre-formed plaque biofilms treated with varying MSZ concentrations. <bold>(F)</bold> Live bacteria ratio for <italic>P. gingivalis</italic> during plaque biofilm formation. <bold>(G)</bold> Live bacteria ratio for <italic>P. gingivalis</italic> in established plaque biofilm. <bold>(H)</bold> CLSM images depicting multispecies plaque biofilm formation and the effects of varying MSZ concentrations on pre-formed plaque biofilms. <bold>(I)</bold> Live bacteria ratio of multispecies plaque biofilm formation. <bold>(J)</bold> Live bacteria ratio of pre-formed multispecies plaque biofilm. Bars marked with (<sup>&#x0002A;&#x0002A;</sup>), (<sup>&#x0002A;&#x0002A;&#x0002A;</sup>), and (<sup>&#x0002A;&#x0002A;&#x0002A;&#x0002A;</sup>) represent significant differences at <italic>p</italic> &#x0003C; 0.01, <italic>p</italic> &#x0003C; 0.001, and <italic>p</italic> &#x0003C; 0.0001, respectively.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-16-1638611-g0001.tif"/>
</fig>
<fig id="F2" position="float">
<label>Figure 4</label>
<caption><p>Effect of MSZ on the bone structure of the maxillary first molar in periodontitis rats. <bold>(A)</bold> Image of a periodontitis model. <bold>(B)</bold> Alveolar bone resorption of the maxillary first molar. The red line marks the CEJ-ABC distance. <bold>(C)</bold> Three-dimensional reconstruction and a sagittal micro-CT section of the maxillary first molar of rats in each group. <bold>(D)</bold> Micro-CT was used to analyze the bone structure parameters including BV/TV, Tb. Th, and Tb. Sp. The bar chart shows the CEJ-ABC distance. <bold>(E)</bold> H&#x00026;E stained images of the periodontium were taken after 2 weeks post-treatment. First row of images (4&#x000D7;). Bars marked with (<sup>&#x0002A;</sup>) show a significant difference at <italic>p</italic> &#x0003C; 0.05.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-16-1638611-g0002.tif"/>
</fig>
<p>The original version of this article has been updated.</p>
</body>
</article>